Nrx pharmaceuticals announces enrollment of first patient in phase ii study of bipolar depression with sub-acute suicidality

Nrx pharmaceuticals, inc., enrolled its first patient in one of two psychiatry studies being initiated this year; this first trial is studying patients with bipolar depression and sub-acute suicidality (not requiring hospitalization). nrx-101 is a patented, fixed dose combination product of d-cycloserine and lurasidone; both are approved drugs that have not shown abuse potential.
NRXP Ratings Summary
NRXP Quant Ranking